NEW YORK (GenomeWeb News) – A few law firms have announced that they are investigating Monogram Biosciences' board of directors for possible breach of fiduciary duty following the firm's announcement yesterday that it has signed a definitive agreement to be acquired by Laboratory Corporation of America for around $107 million.

The law firms — Levi & Korsinsky; Brodsky & Smith; and Howard G. Smith — suggested that the price of the acquisition may not be fair to Monogram's shareholders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.